APH1A
ENSG00000117362
Target class
Enzyme
Chromosome
1
Approved drugs
2
Clinical candidates (approved and in development)
7
- Approved drugs
- 2
- Clinical candidates (approved and in development)
- 7
- Chemical probe available
- No
- Target name
- APH1A
- Gene name
- Aph-1A gamma-secretase subunit
- Gene symbol
- APH1A
- Protein name
- Gamma-secretase subunit APH-1A (APH-1a) (Aph-1alpha) (Presenilin-stabilization factor)
- APH-1A
- CGI-78
- Gene biotype
- Protein coding
- Gene family
- Gamma-secretase complex subunits
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Highest tissue expression
- 157.68
- Tissue specificity (Gini)
- 0.257
- Tissue specificity (tau)
- 0.478
- KEGG gene identifiers
- hsa:51107
- Protein interaction confidence
- 0.878474
- Protein interaction partners
- 19
- R-HSA-1251985
- R-HSA-193692
- R-HSA-205043
- R-HSA-2122948
- R-HSA-2644606
- R-HSA-2894862
- R-HSA-2979096
- R-HSA-3928665
- R-HSA-9013507
- R-HSA-9013700
- R-HSA-9017802
- R-HSA-977225
- R-HSA-9839383
- End position
- 150269580
- Start position
- 150265399
- Chromosome
- 1
- Strand
- Reverse
- Endoplasmic reticulum membrane
- Multi-pass membrane protein . Golgi apparatus, Golgi stack membrane
- Multi-pass membrane protein . Note=Predominantly located in the endoplasmic reticulum and in the cis-Golgi. .
- PubMed 12522139
- PubMed 25043039
- PubMed 26280335
- PubMed 26623517
- PubMed 30598546
- PubMed 30630874
- Tissue specificity (tau)
- 0.477991
- Expression inequality (Gini)
- 0.256609
Expression in transcripts per million
- Skin - Sun Exposed (Lower leg)
- 157.68
- Skin - Not Sun Exposed (Suprapubic)
- 149.4
- Thyroid
- 141.95
- Spleen
- 141.48
- Ovary
- 139.49
Expression in transcripts per million
- Skin - Sun Exposed (Lower leg)157.68
- Skin - Not Sun Exposed (Suprapubic)149.4
- Thyroid141.95
- Spleen141.48
- Ovary139.49
- Lung138.63
- Cells - EBV-transformed lymphocytes138.43
- Esophagus - Mucosa131.57
- Cells - Cultured fibroblasts131.18
- Cervix - Ectocervix128.51
- Vagina127.54
- Cervix - Endocervix125.13
- Nerve - Tibial116.35
- Fallopian Tube111.67
- Breast - Mammary Tissue111.08
- Minor Salivary Gland110.65
- Uterus110
- Adrenal Gland106.22
- Adipose - Subcutaneous106.19
- Small Intestine - Terminal Ileum103.83
- Prostate98.63
- Adipose - Visceral (Omentum)92.47
- Colon - Transverse91.23
- Bladder88.65
- Pituitary85.88
And 29 more, listed on the interactive page.
- GO:0006509
- GO:0007220
- GO:0016485
- GO:0031293
- GO:0034205
- GO:0042982
- GO:0042987
- GO:0005783
- GO:0005789
- GO:0005794
- GO:0005886
- GO:0010008
- GO:0016020
- GO:0070765
- GO:0005515
- GO:0030674
- GO:0061133
Related records
Trials (117)
- A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma
- A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease
- A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease
- A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations
- A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer
- A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery
- A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment
- A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response.
- A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
- A Study Of PF-03084014 In Japanese Patients With Advanced Solid Tumors
- A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy
- A Study of Semagacestat for Alzheimer's Patients
- A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
- A Study to Assess the Effects of 2 Different Prothrombin Complex Concentrates on the Pharmacodynamics of Rivaroxaban in Healthy Adult Volunteers
- A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult Subjects
- A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma
- A Trial In Patients With Advanced Cancer And Leukemia
- A Two-part Study in Edoxaban-treated Healthy Subjects to Establish a Punch Biopsy Bleeding Model and to Evaluate the Effect of a 4-factor Prothrombin Complex Concentrate on Anticoagulation
- Acute Dose-dependent Effects of DMT in Healthy Subjects
Drugs (7)
- Avagacestat Gamma-secretase inhibitor
- Begacestat Gamma-secretase inhibitor
- Nirogacestat Gamma-secretase inhibitor
- Nirogacestat hydrobromide Gamma-secretase inhibitor
- RG-4733 Gamma-secretase inhibitor
- Semagacestat Gamma-secretase inhibitor
- Tarenflurbil Gamma-secretase modulator